for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Limited

TEVA.TA

Latest Trade

4,045.00ILa

Change

139.00(+3.56%)

Volume

668,138

Today's Range

4,040.00

 - 

4,077.00

52 Week Range

2,430.00

 - 

4,709.00

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,906.00
Open
4,040.00
Volume
668,138
3M AVG Volume
25.12
Today's High
4,077.00
Today's Low
4,040.00
52 Week High
4,709.00
52 Week Low
2,430.00
Shares Out (MIL)
1,095.97
Market Cap (MIL)
42,909.60
Forward P/E
4.74
Dividend (Yield %)
--

Next Event

Q4 2020 Teva Pharmaceutical Industries Ltd Earnings Call

Latest Developments

More

Teva, Medincell Announce Positive Results For Risperidone Registration Trial

Tris Pharma Announces US District Court Upholds Validity Of Quillivant XR Patents Rules Teva Infringes Tris Patents

Teva Pharmaceutical Industries Q3 GAAP Loss Per Share $3.97

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Industry

Biotechnology & Drugs

Contact Info

5 Bazel St, P O B 3190

49131

Israel

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Eliyahu Sharon Kalif

Chief Financial Officer, Executive Vice President

Mark Sabag

Executive Vice President, Chief Human Resources Officer and Global Communications and Brand

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.4K

2018

18.9K

2020(E)

16.5K
EPS (USD)

2017

4.010

2019

-0.910

2020(E)

2.520
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.81
Price To Book (MRQ)
1.37
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
267.08
LT Debt To Equity (MRQ)
245.13
Return on Investment (TTM)
-10.98
Return on Equity (TTM)
-8.07

Latest News

Latest News

Teva can't protect blockbuster Copaxone by reclassifying as biologic

Teva Pharmaceutical Industries Ltd has lost a bid to force the U.S. Food and Drug Administration to regulate its blockbuster multiple sclerosis drug Copaxone as a biologic drug, which would have expanded its ability to sue would-be generic rivals.

Law, medicine profs throw support behind Teva's 'skinny label' appeal

Dozens of professors at major universities are urging the full Federal Circuit U.S. Court of Appeals to review an October panel decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though...

Teva settles remaining Intuniv pay-for-delay claims

Teva Pharmaceutical Industries has agreed to settle claims by buyers of Shire's ADHD drug Intuniv accusing Teva's predecessor Actavis and Shire of delaying the launch of a generic version of the drug through an illegal patent lawsuit settlement.

EU fines Teva, Cephalon over pay-for-delay drug deal

The European Commission has fined pharmaceutical company Teva and its now subsidiary Cephalon 60.5 million euros (£54 million) for agreeing to delay a cheaper generic version of Cephalon's sleep disorder medicine.

UPDATE 1-Teva in EU antitrust crosshairs over its Copaxone drug

Israeli drugmaker Teva is the target of an EU antitrust investigation over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, the European Commission said on Friday.

EU antitrust regulators investigating Teva over its Copaxone drug

EU antitrust regulators are investigating Israeli drugmaker Teva over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, the European Commission said on Friday.

Teva Pharm third-quarter profit in line with forecasts, lowers 2020 revenue outlook

Israel-based Teva Pharmaceutical Industries <TEVA.TA> reported quarterly profit in line with expectations but lowered its 2020 revenue forecast on lower demand for some products as fewer people are going to hospitals and doctors during the pandemic.

Japan's Sosei allies with ex-Novartis team to develop neurological drug pipeline

Japan's Sosei Group Corp said on Monday it is allying with a U.S. biotech run by former Novartis AG executives to commercialise a neurological drug pipeline.

BRIEF-U.S. Settles With Oxycontin Drugmaker Purdue Pharma Over Opioids -Document

* U.S. SETTLES WITH OXYCONTIN DRUGMAKER PURDUE PHARMA OVER OPIOIDS -DOCUMENT Source text for Eikon: Further company coverage:

U.S. appeals court revives Glaxo $235.5 million verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc $235.5 million for selling a generic version of Glaxo's heart drug Coreg.

BRIEF-Teva plans to appeal verdict favoring Glaxo concerning Coreg drug

Teva says it plans to appeal u.s. Court's reinstatement of jury verdict favoring glaxosmithkline, and plans to present additional defenses related to the drug coreg

U.S. appeals court revives GlaxoSmithKline verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg.

New York charges Johnson & Johnson with insurance fraud over opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

Teva to pay $20 mln to settle Intuniv pay-for-delay claims

Teva Pharmaceutical Industries has agreed to pay $20 million to settle claims by direct purchasers of Shire's ADHD drug Intuniv to settle claims that Teva's predecessor, Actavis, and Shire delayed launch of a generic version of the drug with an illegal patent lawsuit settlement...

After seeing 'damning' report, opioid plaintiffs seek sanctions for Allergan, Teva

Cities and states suing drug manufacturers and distributors in a national multidistrict litigation over their role in the opioid epidemic have asked a judge to sanction Allergan and Teva Pharmaceutical Industries for withholding key evidence.

U.S. charges Teva in generic drugs price-fixing probe

The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd <TEVA.TA> on Tuesday with conspiring with competitors to raise prices for generic drugs.

U.S. charges founder of drug company bought by Teva in insider trading case

U.S. prosecutors brought insider trading charges against the founder and former chief executive of Auspex Pharmaceuticals Inc, accusing him of providing illegal tips to friends and family as Teva Pharmaceutical Industries Ltd <TEVA.TA> prepared to buy his company in a $3.5...

US charges ex-CEO of drug company with fraud tied to Teva tender offer

U.S. prosecutors on Tuesday announced insider trading charges accusing the former chief executive of Auspex Pharmaceuticals Inc with tipping friends and family about an anticipated tender offer for his company by Teva Pharmaceutical Industries Ltd in 2015.

U.S. to charge Teva in generic drugs price-fixing probe: Bloomberg Law

U.S. Justice Department is preparing to charge Teva Pharmaceutical Industries Ltd with conspiring with competitors to raise prices for generic drugs, Bloomberg Law reported on Tuesday citing a person familiar with the matter.

New York charges Teva, Allergan with insurance fraud over opioid claims

New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up